Immune thrombocytopenia in adolescents and young adults

TL;DR

This paper highlights the need for tailored treatment strategies for adolescents and young adults with immune thrombocytopenia, as they differ from both children and adults.

Contribution

The paper introduces a collaborative effort to analyze ITP in AYAs using multi-center registries to address the lack of specific data for this group.

Findings

AYAs with ITP have distinct clinical features that require age-specific treatment approaches.

Four analyses have been conducted on major clinical aspects of ITP in AYAs using data from 2004 to 2021.

The AYAs collaboration aims to improve long-term outcomes and quality of life through age-adapted trials.

Abstract

Previous guidelines for the treatment of immune thrombocytopenia (ITP) have traditionally focused on a dichotomy between pediatric and adult ITP. Adolescents and young adults (AYAs) do not neatly fit into either the pediatric or adult ITP group. A deeper understanding of ITP’s natural history, risk factors for chronicity, and outcomes in AYAs is a crucial first step toward developing tailored treatment algorithms. Such data could form the basis for recommendations targeting this underrepresented yet clinically distinct population. Ultimately, age-adapted trials may improve long-term outcomes, reduce toxicity, and enhance quality of life for AYAs with ITP. The AYAs collaboration—drawing on data from the Pediatric and Adult Registry on Chronic ITP (PARC-ITP), Registre Midi- Pyrénéen-France (CARMEN-France) adult registry in Toulouse, and the National Prospective Cohort for Children with Chronic Autoimmune Cytopenia (OBS’CEREVANCE) in Bordeaux, France—aims to address the information gap in AYAs with ITP. To date, four analyses have been undertaken (using data from 2004 to 2021), each addressing the major clinical aspects of ITP in patients aged 12–25 years: (1) newly diagnosed ITP, (2) chronic disease, (3) refractory courses, and (4) secondary (sITP) forms.

Figures